IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ANDREOLI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.581
EU - Europa 6.076
AS - Asia 2.454
SA - Sud America 28
AF - Africa 23
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 18.194
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.552
DE - Germania 2.039
UA - Ucraina 1.170
CN - Cina 1.040
PL - Polonia 732
IT - Italia 603
SG - Singapore 578
HK - Hong Kong 431
FI - Finlandia 339
RU - Federazione Russa 338
TR - Turchia 258
GB - Regno Unito 241
IE - Irlanda 230
FR - Francia 176
SE - Svezia 71
IN - India 46
VN - Vietnam 26
CA - Canada 23
CZ - Repubblica Ceca 18
NL - Olanda 18
AU - Australia 16
BE - Belgio 15
BR - Brasile 15
EU - Europa 15
GR - Grecia 13
ES - Italia 12
HR - Croazia 11
EG - Egitto 10
ID - Indonesia 10
CH - Svizzera 7
JP - Giappone 7
MK - Macedonia 7
TH - Thailandia 7
AE - Emirati Arabi Uniti 6
PH - Filippine 6
RS - Serbia 6
AR - Argentina 5
KR - Corea 5
PK - Pakistan 5
PT - Portogallo 5
RO - Romania 5
DK - Danimarca 4
HU - Ungheria 4
IQ - Iraq 4
SA - Arabia Saudita 4
BG - Bulgaria 3
GE - Georgia 3
IR - Iran 3
MY - Malesia 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
AT - Austria 2
CI - Costa d'Avorio 2
DZ - Algeria 2
EC - Ecuador 2
JM - Giamaica 2
KZ - Kazakistan 2
LY - Libia 2
MA - Marocco 2
MU - Mauritius 2
MX - Messico 2
PE - Perù 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
GS - Georgia del Sud e Isole Sandwich Australi 1
GT - Guatemala 1
IL - Israele 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
TW - Taiwan 1
UG - Uganda 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 18.194
Salva come PNG Salva come JPEG
Città #
Fairfield 1.489
Woodbridge 1.174
Jacksonville 828
Houston 809
Warsaw 729
Ashburn 717
Seattle 561
Cambridge 544
Wilmington 508
Ann Arbor 491
Singapore 453
Princeton 439
Hong Kong 426
Chandler 346
New York 271
Istanbul 237
Dublin 230
Helsinki 229
Nanjing 223
Beijing 180
Nürnberg 102
Brescia 99
Nanchang 99
San Diego 98
Des Moines 89
Changsha 74
Shanghai 70
Shenyang 66
Hebei 65
Lancaster 58
Milan 58
Munich 41
Jinan 39
London 36
Dearborn 32
Jiaxing 32
Bergamo 26
Tianjin 26
Hangzhou 25
Dong Ket 24
Verona 24
Romola 23
San Francisco 22
Los Angeles 21
Kunming 20
Zhengzhou 20
Boardman 18
Toronto 18
Brno 17
Taizhou 16
Brussels 14
Haikou 14
Lanzhou 14
Ningbo 12
Rome 11
Split 11
Orange 10
Augusta 9
Hanover 9
Melbourne 9
Pune 9
Jakarta 8
Kocaeli 8
Guangzhou 7
Norwalk 7
Siena 7
Chicago 6
Detroit 6
Hounslow 6
Kilburn 6
Lappeenranta 6
Redwood City 6
San Mateo 6
Tokyo 6
Acton 5
Chiswick 5
Falkenstein 5
Fuzhou 5
Strasbourg 5
Taiyuan 5
Alexandria 4
Bosio 4
Cologne 4
Faisalabad 4
Gunzenhausen 4
Napoli 4
Parabiago 4
Phoenix 4
Prescot 4
Redmond 4
Rende 4
Sutton Coldfield 4
Sydney 4
Turin 4
Walnut 4
Washington 4
Amsterdam 3
Arbil 3
Arcos De La Frontera 3
Ardabil 3
Totale 12.555
Salva come PNG Salva come JPEG
Nome #
Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases. 259
9A.07: CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS. ARE THERE ANY DIFFERENCES? 255
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 245
The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation 205
Long-term outcome of children of rheumatic disease patients 173
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 166
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 164
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 159
Antirheumatic drugs and reproduction in women and men with chronic arthritis. 156
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome 152
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. 149
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends 147
Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus. 143
The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus 135
Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome 131
A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus 131
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. 130
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 130
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus 130
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. 129
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 128
Antiphospholipid antibodies mediate autoimmunity against dying cells. 127
Inflammatory molecules: A target for treatment of systemic autoimmune diseases. 125
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. 125
Children born to SLE and APS mothers 125
Anti-phospholipid antibodies 123
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 122
Management of thrombotic and obstetric antiphospholipid syndrome: A systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults 122
25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. 120
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 120
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes 119
Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. 118
Management of recurrent thrombosis in antiphospholipid syndrome 118
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 117
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? 115
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 115
Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 114
Beyond the "syndrome": antiphospholipid antibodies as risk factors. 114
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 114
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. 113
State of the art: Reproduction and pregnancy in rheumatic diseases. 112
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D 112
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 112
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. 111
Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis 111
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 111
Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. 109
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 109
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. 109
Neonatal effects of maternal antiphospholipid syndrome. 108
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 108
Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome 108
Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. 107
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. 107
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 107
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 107
Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 106
Pregnancy in patients with autoimmune disease: A reality in 2016 106
Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: Results from a multicenter study of 283 pregnancies 105
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 104
European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO) 104
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? 103
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 103
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. 103
Predictors of maternal and fetal complications in SLE patients: a prospective study 103
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7 103
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 103
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 102
The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases 102
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 101
PROSPECTIVELY FOLLOWED PREGNANCIES IN PATIENTS WITH SYSTEMIC VASCULITIS: STILL MANY PROBLEMS ON BOTH FOETAL AND MATERNAL SIDE 100
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 98
ANTI-BETA2 GLYCOPROTEIN I-DOMAIN 1 AUTOANTIBODIES: COMPARISON BETWEEN TWO METHODS OF DETECTION 98
EFFICACY AND SAFETY OF CYCLOSPORINE-A DURING PREGNANCY IN AUTOIMMUNE DISEASES 97
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases 97
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al 96
DIAGNOSTIC PERFORMANCE OF TWO AUTOMATED ASSAY PANELS FOR ANTICARDIOLIPIN AND ANTI-BETA2GLYCOPROTEIN I ANTIBODIES IN THE LABORATORY DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME 94
DOMAIN 1 IS THE MAIN SPECIFICITY OF ANTI-BETA2GPI ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES 93
Pathophysiological role and therapeutic implications of vitamin d in autoimmunity: Focus on chronic autoimmune diseases 93
Vitamin D and antiphospholipid syndrome. 92
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study 92
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 91
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study 91
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 91
Long-term outcome of children born from mothers with autoimmune diseases 91
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 90
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study 89
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases 88
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 87
Update on Antiphospholipid Syndrome: Ten Topics in 2017 87
WINTER LUPUS FLARES ARE ASSOCIATED WITH LOWER VITAMIN D LEVELS IN A RETROSPECTIVE LONGITUDINAL STUDY OF ITALIAN PATIENTS 85
The estimated frequency of Antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review 85
A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP 84
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 84
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy 84
Domain 1 Is The Main Specificity Of Anti-b2glycoprotein I Antibodies In Systemic Autoimmune Diseases. 83
The antiphospholipid syndrome in patients with systemic lupus erythematosus 83
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 83
The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature 83
LONG TERM OUTCOME IN CHILDREN BORN TO MOTHERS WITH SYSTEMIC LUPUS ERYTEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME 81
Totale 11.569
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.395 0 0 0 0 214 383 313 395 272 454 130 234
2020/20213.598 51 409 248 527 182 422 113 354 331 473 312 176
2021/20221.763 114 280 54 102 20 102 57 132 103 206 172 421
2022/20231.285 248 16 32 58 125 377 5 107 176 4 65 72
2023/20241.814 108 64 144 158 66 345 56 78 456 33 26 280
2024/20251.120 84 71 66 530 369 0 0 0 0 0 0 0
Totale 18.625